Genedrive plc (LSE:GDR) has received approximately £0.76 million from HMRC through the UK’s research and development tax credit programme, providing additional funding to support the continued development and commercial expansion of its point-of-care genetic testing platform.
The payment relates to the company’s financial years ended 30 June 2024 and 30 June 2025 and represents a non-dilutive source of capital that strengthens its financial position as it seeks to broaden adoption of its precision medicine technologies in the UK and overseas markets.
Funding supports expansion of pharmacogenetic testing
The Manchester-based diagnostics company focuses on rapid pharmacogenetic tests designed to enable more personalised prescribing decisions at the point of care. Management said the tax credit proceeds will bolster the balance sheet and provide further resources to support both product development and commercial growth initiatives.
Genedrive continues to target opportunities in emergency and acute healthcare settings, where rapid genetic testing can help clinicians make treatment decisions more quickly and improve patient outcomes.
NHS-backed products form foundation of growth strategy
The company has established a portfolio that includes two CE-IVD approved diagnostic assays that have also received recommendations from the National Institute for Health and Care Excellence (NICE).
One test is designed to identify stroke patients who may not respond effectively to the antiplatelet drug Clopidogrel, helping clinicians select more appropriate treatments. The second aims to reduce the risk of antibiotic-induced hearing loss in newborns by identifying patients with a genetic susceptibility before treatment begins.
By enabling more targeted prescribing decisions, the company believes its products can improve clinical outcomes while helping healthcare providers reduce costs and operational pressures.
Financial challenges remain despite positive operational progress
Although the latest tax credit payment provides additional financial flexibility, Genedrive’s outlook continues to be affected by ongoing losses, persistent cash burn and a declining equity base. These factors remain key considerations for investors despite the company maintaining relatively low levels of debt.
Technical indicators offer a more balanced picture, with the share price trading above major moving averages and momentum signals remaining broadly neutral. However, valuation support remains limited as the company continues to report negative earnings and does not currently offer a dividend.
More about Genedrive
Genedrive plc is a UK-based commercial-stage pharmacogenetic diagnostics company specialising in rapid point-of-care testing technologies. Its proprietary platform supports genetic assays designed to improve prescribing decisions in emergency and acute care settings. The company’s products include two CE-IVD approved and NICE-recommended tests currently used within the NHS, and it is focused on expanding the adoption of precision diagnostics both domestically and internationally.
Leave a Reply